A novel quantitative kinase assay using bacterial surface display and flow cytometry

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Henriques, Sónia Troeira ^a   Thorstholm, Louise ^a   Huang, Yen Hua ^a   Getz, Jennifer A ^b   Daugherty, Patrick S ^b   Craik, David J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; CELL SURFACE DISPLAY TECHNIQUES; ENZYME ACTIVATION; ENZYME ASSAYS; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; KINETICS; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; PHOSPHOTRANSFERASES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY;

EID: 84894070898     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080474     Document Type: Article

References (29)

1. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411: 355-365. doi:10.1038/35077225. (Pubitemid 32467045)
2. Levitzki A, Mishani E (2006) Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 75: 93-109. doi:10.1146/annurev.biochem.75.103004. 142657. (Pubitemid 44118027)
3. Cohen P (2002) Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 1: 309-315. doi:10.1038/nrd773.
4. Westin JR, Kurzrock R (2012) It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther 11: 2549-2555. doi:10.1158/1535-7163.MCT-12-0473.
5. Carmi C, Mor M, Petronini PG, Alfieri RR (2012) Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem Pharmacol 84: 1388-1399. doi:10.1016/j.bcp.2012.07.031.
6. Fainstein E, Marcelle C, Rosner A, Canaani E, Gale RP, et al. (1987) A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. Nature 330: 386-388. doi:10.1038/330386a0. (Pubitemid 18045468)
7. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830.
8. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, et al. (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100-104.
9. Druker BJ (2001) Current treatment approaches for chronic myelogenous leukemia. Cancer J 7 Suppl 1: S14-S18.
10. Druker BJ, Lydon NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3-7. doi:10.1172/JCI9083. (Pubitemid 30036380)
11. Hughes T, Branford S (2006) Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 20: 29-41. doi:10.1016/j.blre.2005.01.008. (Pubitemid 43106716)
12. Bixby D, Talpaz M (2009) Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program: 461-476. doi:10.1182/asheducation-2009.1.461.
13. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, et al. (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62: 4236-4243. (Pubitemid 34827278)
14. Fava C, Rege-Cambrin G, Saglio G (2012) Chronic myeloid leukemia: state of the art in 2012. Curr Oncol Rep 14: 379-386. doi:10.1007/s11912-012-0253-9.
15. Jain P, Kantarjian H, Cortes J (2013) Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol 14: 127-143. doi:10.1007/s11864-013-0234-8.
16. Bogoyevitch MA, Barr RK, Ketterman AJ (2005) Peptide inhibitors of protein kinases-discovery, characterisation and use. Biochim Biophys Acta 1754: 79-99. doi:10.1016/j.bbapap.2005.07.025. (Pubitemid 41797689)
17. Chapelat J, Berst F, Marzinzik AL, Moebitz H, Drueckes P, et al. (2012) The Substrate-Activity-Screening methodology applied to receptor tyrosine kinases: a proof-of-concept study. Eur J Med Chem 57: 1-9. doi:10.1016/j.ejmech. 2012.08.038.
18. Ma H, Deacon S, Horiuchi K (2008) The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin Drug Discov 3: 607-621. doi:10.1517/17460441.3.6.607. (Pubitemid 351890673)
19. Jia Y, Quinn CM, Kwak S, Talanian RV (2008) Current in vitro kinase assay technologies: the quest for a universal format. Curr Drug Discov Technol 5: 59-69. (Pubitemid 351364574)
20. Min D-H, Su J, Mrksich M (2004) Profiling kinase activities by using a peptide chip and mass spectrometry. Angew Chem Int Ed Engl 43: 5973-5977. doi:10.1002/anie.200461061. (Pubitemid 39551335)
21. Chen H, Adams E, Van Schepdael A (2012) LC-ESI-MS method for the monitoring of Abl 1 tyrosine kinase. J Chromatogr B Analyt Technol Biomed Life Sci 897: 17-21. doi:10.1016/j.jchromb.2012.04.001.
22. Ji L, Wu J-H, Luo Q, Li X, Zheng W, et al. (2012) Quantitative mass spectrometry combined with separation and enrichment of phosphopeptides by titania coated magnetic mesoporous silica microspheres for screening of protein kinase inhibitors. Anal Chem 84: 2284-2291. doi:10.1021/ac202897u.
23. Inamori K, Kyo M, Nishiya Y, Inoue Y, Sonoda T, et al. (2005) Detection and quantification of on-chip phosphorylated peptides by surface plasmon resonance imaging techniques using a phosphate capture molecule. Anal Chem 77: 3979-3985. doi:10.1021/ac050135t. (Pubitemid 40934261)
24. Li Y, Xie W, Fang G (2008) Fluorescence detection techniques for protein kinase assay. Anal Bioanal Chem 390: 2049-2057. doi:10.1007/s00216-008-1986-z.
25. Songyang Z, Carraway KL, Eck MJ, Harrison SC, Feldman RA, et al. (1995) Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373: 536-539. doi:10.1038/373536a0.
26. Rice JJ, Daugherty PS (2008) Directed evolution of a biterminal bacterial display scaffold enhances the display of diverse peptides. Protein Eng Des Sel 21: 435-442. doi:10.1093/protein/gzn020. (Pubitemid 351882133)
27. Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, et al. (2005) A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 102: 1992-1997. doi:10.1073/pnas.0408283102. (Pubitemid 40262000)
28. Zhou G, Sylvester JE, Wu D, Veach DR, Kron SJ (2011) A magnetic bead-based protein kinase assay with dual detection techniques. Anal Biochem 408: 5-11. doi:10.1016/j.ab.2010.08.034.
29. Daugherty PS (2007) Protein engineering with bacterial display. Curr Opin Struct Biol 17: 474-480. doi:10.1016/j.sbi.2007.07.004.